Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Aug 20, 2026
Olema Pharmaceuticals (OLMA) Holds Near $11.31 as Phase 3 Data Timeline Extends into 2027

Olema Pharmaceuticals (OLMA) Holds Near $11.31 as Phase 3 Data Timeline Extends into 2027

Key Takeaways

  • OLMA shares have been essentially flat over the trailing 30 days, trading near $11.31 in mid-August 2026 — a low single-digit move that supports an overview rather than a price-driven narrative.
  • The pivotal Phase 3 OPERA-01 trial for palazestrant completed enrollment, with top-line data now expected in the first quarter of 2027, resetting the near-term catalyst timeline.
  • Second-quarter results showed a wider net loss driven by higher clinical development spending, while cash and marketable securities stood at $461.1 million as of June 30, 2026.
  • Olema presented initial Phase 1 data for OP-3136 and expanded its clinical footprint through a collaboration with Bayer.
  • Analyst sentiment remains broadly constructive, with a "Moderate Buy" consensus, even as several firms trimmed price targets.

Where OLMA Stands in the Market Right Now

From what I see, Olema Pharmaceuticals (NASDAQ: OLMA) traded near $11.31 in mid-August 2026, with a market capitalization of roughly $990 million. The shares sit well below their 52-week high of $36.26 and above the 52-week low of $5.34, reflecting a stock that has swung sharply with clinical news flow over the past year. Over the trailing 30 days, the price has moved only a few percentage points, holding in a comparatively narrow range as investors digest an evolving catalyst calendar. A post-earnings gap lower in early August was followed by a partial recovery, leaving the stock broadly in line with its late-July levels. This muted short-term move places the focus on the company's late-stage oncology pipeline rather than on short-term price momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Olema’s Pipeline Focus and Competitive Edge

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, with a primary emphasis on estrogen receptor-positive (ER+), HER2-negative breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available small molecule that acts as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). Palazestrant is being evaluated as a monotherapy in the pivotal Phase 3 OPERA-01 trial and in combination with ribociclib in the Phase 3 OPERA-02 trial, with additional Phase 1/2 combination studies underway.

The company's second clinical candidate, OP-3136, is an oral inhibitor of KAT6, an epigenetic target dysregulated in breast and other cancers. Investors follow OLMA for its differentiated approach to endocrine-driven cancers and its potential to address acquired resistance to existing endocrine therapies — a meaningful clinical and commercial opportunity in a competitive but high-demand oncology space.

Recent Events Reshaping the OLMA Story

Several verified events have shaped investor sentiment over the past 30 days. The most consequential was the August 11, 2026 disclosure that Olema completed enrollment in the pivotal Phase 3 OPERA-01 trial while pushing top-line data expectations into the first quarter of 2027. The extended timeline triggered a sharp single-day decline as the market repriced the timing of the company's most important binary catalyst.

That news followed second-quarter results reported on August 10, 2026, when Olema posted a net loss of $63.2 million, up from $43.8 million a year earlier, and reported an EPS loss of $0.61, missing the consensus estimate of a $0.55 loss. The higher spend reflected investment in late-stage development of palazestrant and advancement of OP-3136. The company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities.

On the scientific front, Olema presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting. Earlier in the year, the company entered a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with darolutamide (Nubeqa) in patients with metastatic castration-resistant prostate cancer. Olema's addition to multiple Russell growth indices in June 2026 also broadened its institutional visibility. Against this backdrop, several analysts maintained Buy or Overweight ratings while lowering price targets to reflect the revised data timeline. I reviewed some of the sector context with Tickeron’s AI Daily Buy/Sell Signals to gauge broader sentiment around similar names.

What to Watch for OLMA Through the Rest of 2026

Looking ahead, the dominant driver for OLMA remains the Phase 3 OPERA-01 readout now expected in the first quarter of 2027, which makes near-term catalysts more dependent on earlier-stage data. Investors will closely monitor continued progress in OPERA-02, the palazestrant and ribociclib combination study, as well as expanding Phase 1 data for OP-3136, including combination readouts stemming from the Bayer collaboration.

Cash management is another key consideration: with $461.1 million on hand as of mid-2026 and a meaningful clinical spend, funding runway and potential dilution remain central to the investment case. Regulatory designations, medical conference presentations, and broader biotech financing conditions will also influence sentiment. As analyst price targets remain well above the current share price but have been trimmed in response to the revised timeline, the stock's trajectory is likely to remain tied to clinical execution and data delivery rather than near-term earnings.

Using AI Tools to Track Biotech Names

In my own research process, I’ve turned to Tickeron’s Trending AI Robots page to review how top-performing automated strategies are navigating volatility in sectors like biotechnology. The selection highlights bots with varying timeframes and risk profiles, offering a practical lens on how different approaches might align with holdings such as OLMA.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OLMA

OLMA sees MACD Histogram just turned negative

OLMA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 39 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OLMA as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

OLMA moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OLMA crossed bearishly below the 50-day moving average on August 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OLMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for OLMA entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where OLMA advanced for three days, in 228 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

OLMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.996) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.043).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. OLMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OLMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 7%. NRSN experienced the highest price growth at 1,794%, while LGVN experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 108%. For the same stocks of the Industry, the average monthly volume growth was 48% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
OLMA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
780 Brannan Street
Phone
+1 415 651-3316
Employees
131
Web
https://www.olema.com
Interact to see
Advertisement
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.